In particular, the ABCSG-18 trial assessed the efficacy of denosumab alongside aromatase inhibitors in post-menopausal women with early breast cancer, showing an improvement in disease-free survival, including for bone metastases [20]. Here, CYP19A1 is linked to breast cancer.